Operates ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. Provides customized medications to meet specific patient needs. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 39% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades 40% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 39% a year on average.
Sales run at $272.3M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 13 buys and 11 sells. Management buying with its own money is usually read as a good sign.
A loss of $5.1M against $272.3M in annual sales.
Against everything we grade, HROW lands somewhere in the middle. The grade moves as the numbers move.
The takeaway: HROW is a high-risk stock — not yet profitable, and its future rides on its product catching on.